[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3355884T3 - Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler - Google Patents

Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler Download PDF

Info

Publication number
DK3355884T3
DK3355884T3 DK16852640.8T DK16852640T DK3355884T3 DK 3355884 T3 DK3355884 T3 DK 3355884T3 DK 16852640 T DK16852640 T DK 16852640T DK 3355884 T3 DK3355884 T3 DK 3355884T3
Authority
DK
Denmark
Prior art keywords
antiostrogen
pyrido
indol
tetrahydro
medicines
Prior art date
Application number
DK16852640.8T
Other languages
English (en)
Inventor
David C Myles
Peter J Kushner
Cyrus L Harmon
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3355884T3 publication Critical patent/DK3355884T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16852640.8T 2015-10-01 2016-09-29 Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler DK3355884T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01
PCT/US2016/054549 WO2017059139A1 (en) 2015-10-01 2016-09-29 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS

Publications (1)

Publication Number Publication Date
DK3355884T3 true DK3355884T3 (da) 2021-08-02

Family

ID=58427985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16852640.8T DK3355884T3 (da) 2015-10-01 2016-09-29 Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler

Country Status (24)

Country Link
US (5) US10292971B2 (da)
EP (2) EP3355884B1 (da)
JP (3) JP6776348B2 (da)
KR (2) KR102710603B1 (da)
CN (2) CN113248494A (da)
AU (3) AU2016331065B2 (da)
BR (2) BR122023020677A2 (da)
CA (1) CA3000410A1 (da)
CL (1) CL2018000827A1 (da)
CY (1) CY1124669T1 (da)
DK (1) DK3355884T3 (da)
ES (1) ES2881398T3 (da)
HR (1) HRP20211124T1 (da)
HU (1) HUE055321T2 (da)
IL (3) IL286518B2 (da)
LT (1) LT3355884T (da)
MX (2) MX2018003929A (da)
PL (1) PL3355884T3 (da)
PT (1) PT3355884T (da)
RS (1) RS62133B1 (da)
RU (2) RU2021107754A (da)
SI (1) SI3355884T1 (da)
UA (1) UA122346C2 (da)
WO (1) WO2017059139A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI699363B (zh) 2014-12-18 2020-07-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并［３，４-ｂ］吲哚雌激素受體調節劑及其用途
US10292971B2 (en) * 2015-10-01 2019-05-21 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
PT3386500T (pt) 2015-12-09 2023-01-06 Univ Illinois Supressores seletivos do recetor de estrogénio à base de benzotiofeno
CA3012078C (en) * 2016-02-05 2024-01-30 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
WO2018049042A1 (en) * 2016-09-07 2018-03-15 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells
CN114656464B (zh) 2016-10-24 2024-10-15 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
PL3494116T3 (pl) 2017-01-30 2020-04-30 Astrazeneca Ab Modulatory receptora estrogenowego
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
HRP20230859T1 (hr) 2018-06-21 2023-11-10 F. Hoffmann - La Roche Ag Kruti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2hpirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, postupak njihove proizvodnje i postupci njihove primjene u liječenju raka
JP7524506B2 (ja) 2018-10-15 2024-07-30 トーヨーカネツ株式会社 搬送情報システム、プログラム、及び記録媒体
EP3902545A4 (en) 2018-12-24 2022-06-22 InventisBio Co., Ltd. NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3144791A1 (en) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
US11848549B2 (en) * 2020-09-15 2023-12-19 Easy Solar Products, Inc. Junction box with flashing for a tile surface
WO2022140744A1 (en) 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
CN116744920A (zh) * 2021-02-08 2023-09-12 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023283329A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2024039858A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024039860A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039861A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024076626A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024124182A1 (en) * 2022-12-09 2024-06-13 Olema Pharmaceuticals, Inc. Dosage forms of an estrogen receptor antagonist

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
EP0705832B1 (en) 1994-09-12 2003-08-13 Eli Lilly And Company Limited Serotonergic modulators
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
BR0112360A (pt) 2000-07-06 2003-05-06 Wyeth Corp Método para aumentar a atividade da sintase de óxido nìtrico
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
MXPA02012896A (es) 2000-07-06 2003-10-24 Wyeth Corp Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
CA2414938A1 (en) 2000-07-06 2002-01-17 Simon Nicholas Jenkins Combinations of ssri and estrogenic agents
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
EE200400061A (et) 2001-08-11 2004-04-15 Bristol-Myers Squibb Pharma Company Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised
EP1720862A1 (en) 2004-02-03 2006-11-15 Eli Lilly And Company Kinase inhibitors
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
CN102408425A (zh) * 2004-03-15 2012-04-11 Ptc医疗公司 用于抑制血管生成的咔啉衍生物及其应用
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7399767B2 (en) 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
CN102480957A (zh) 2009-05-27 2012-05-30 Ptc医疗公司 治疗癌症及非肿瘤病症的方法
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
AU2011347718B2 (en) * 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
KR20140101399A (ko) * 2011-12-14 2014-08-19 세라곤 파마슈티컬스, 인크. 불화 에스트로겐 수용체 조절제 및 이의 용도
KR20140103335A (ko) 2011-12-16 2014-08-26 올레마 파마슈티컬스 인코포레이티드 신규한 벤조피란 화합물, 조성물 및 이의 용도
DK3004090T3 (da) 2013-05-28 2018-01-08 Astrazeneca Ab Kemiske forbindelser
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
PE20160157A1 (es) 2013-06-19 2016-03-18 Seragon Pharmaceuticals Inc Moduladores de los receptores de estrogeno y sus usos
KR20160021281A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 아제티딘 에스트로겐 수용체 조절제 및 이의 용도
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112017008410A2 (pt) * 2014-10-23 2017-12-19 Oy Mtg Meltron Ltd aparelho de iluminação para áreas perigosas
KR101989608B1 (ko) * 2014-10-31 2019-06-14 카스턴 매뉴팩츄어링 코오포레이숀 골프 클럽 헤드의 그루브 및 골프 클럽 헤드의 그루브의 제조 방법
TWI699363B (zh) * 2014-12-18 2020-07-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并［３，４-ｂ］吲哚雌激素受體調節劑及其用途
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10292971B2 (en) 2015-10-01 2019-05-21 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
EP3472159A1 (en) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN114656464B (zh) 2016-10-24 2024-10-15 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
HRP20230080T1 (hr) 2018-07-12 2023-03-17 Eli Lilly And Company Selektivna sredstva za razgradnju estrogenskog receptora
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
CY1124669T1 (el) 2022-07-22
IL286518B1 (en) 2024-02-01
IL286518A (en) 2021-10-31
US20240226073A9 (en) 2024-07-11
EP3912680A1 (en) 2021-11-24
US11229630B2 (en) 2022-01-25
AU2021206861B2 (en) 2023-02-02
JP2021001231A (ja) 2021-01-07
HRP20211124T1 (hr) 2021-10-15
KR20180071274A (ko) 2018-06-27
AU2016331065B2 (en) 2021-04-29
RU2021107754A (ru) 2021-04-01
US11672785B2 (en) 2023-06-13
MX2021005214A (es) 2021-06-18
UA122346C2 (uk) 2020-10-26
CN108366996A (zh) 2018-08-03
US20240131013A1 (en) 2024-04-25
KR20240142622A (ko) 2024-09-30
AU2021206861A1 (en) 2021-08-12
CN113248494A (zh) 2021-08-13
BR112018006121A2 (pt) 2018-10-23
AU2016331065A1 (en) 2018-04-26
IL258363B (en) 2021-10-31
WO2017059139A1 (en) 2017-04-06
SI3355884T1 (sl) 2021-11-30
US20180289679A1 (en) 2018-10-11
CL2018000827A1 (es) 2018-09-28
PL3355884T3 (pl) 2021-11-29
RU2745742C1 (ru) 2021-03-31
MX2018003929A (es) 2018-11-22
US20210059991A1 (en) 2021-03-04
JP2018530549A (ja) 2018-10-18
EP3355884A4 (en) 2019-06-05
JP7277424B2 (ja) 2023-05-19
US10292971B2 (en) 2019-05-21
US10624878B2 (en) 2020-04-21
BR122023020677A2 (pt) 2023-12-12
EP3355884A1 (en) 2018-08-08
IL258363A (en) 2018-05-31
LT3355884T (lt) 2021-07-26
RS62133B1 (sr) 2021-08-31
AU2023202620A1 (en) 2023-05-18
US20220370421A1 (en) 2022-11-24
EP3355884B1 (en) 2021-04-28
HUE055321T2 (hu) 2021-11-29
CN108366996B (zh) 2021-04-09
JP6776348B2 (ja) 2020-10-28
IL286518B2 (en) 2024-06-01
PT3355884T (pt) 2021-07-26
CA3000410A1 (en) 2017-04-06
US20190247372A1 (en) 2019-08-15
JP2023087106A (ja) 2023-06-22
ES2881398T3 (es) 2021-11-29
IL310489A (en) 2024-03-01
BR112018006121B1 (pt) 2024-01-23
KR102710603B1 (ko) 2024-09-27

Similar Documents

Publication Publication Date Title
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
DOP2018000256A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
FIC20240025I1 (fi) Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
CL2016000752S1 (es) Bicicleta.
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
BR112016023628A2 (pt) composições farmacêuticas.
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
KR20180084876A (ko) 내플라즈마성 부재
ES1150114Y (es) Abarcón.
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (zh) 2，3，4，5-四氫吡啶-6-胺衍生物
CL2015002617S1 (es) Motocicleta.
DK3057373T3 (da) Enkeltcelle-punkt-til-multipunkt-overførsel
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
ES1202236Y (es) Bombona
BR112017018293A2 (pt) brocas dentárias.
ES1168709Y (es) Percha
CL2016000824S1 (es) Motocicleta.
ES1158559Y (es) Percha
ITUA20161619A1 (it) Motociclo.
FI11402U1 (fi) Sulkemislaite
UA33724S (uk) Пляшка фігурна